Literature DB >> 17942307

New 1,8-naphthyridine and quinoline derivatives as CB2 selective agonists.

Clementina Manera1, Maria Grazia Cascio, Veronica Benetti, Marco Allarà, Tiziano Tuccinardi, Adriano Martinelli, Giuseppe Saccomanni, Elisa Vivoli, Carla Ghelardini, Vincenzo Di Marzo, Pier Luigi Ferrarini.   

Abstract

A series of new 1,8-naphthyridine and quinoline derivatives were synthesized and evaluated for their cannabinoid receptor affinity. In particular, compounds 2, 5, 11, and 13 showed a high CB(2) affinity and CB(2) versus CB(1) selectivity, in agreement with molecular modeling studies. Furthermore, compound 2 also exhibited in vivo antinociceptive effects.

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17942307     DOI： 10.1016/j.bmcl.2007.09.089

Source DB:  PubMed          Journal:  Bioorg Med Chem Lett        ISSN： 0960-894X            Impact factor:   2.823


  8 in total

1.  Discovery and SAR of muscarinic receptor subtype 1 (M1) allosteric activators from a molecular libraries high throughput screen. Part 1: 2,5-dibenzyl-2H-pyrazolo[4,3-c]quinolin-3(5H)-ones as positive allosteric modulators.

Authors:  Changho Han; Arindam Chatterjee; Meredith J Noetzel; Joseph D Panarese; Emery Smith; Peter Chase; Peter Hodder; Colleen Niswender; P Jeffrey Conn; Craig W Lindsley; Shaun R Stauffer
Journal:  Bioorg Med Chem Lett       Date:  2014-11-18       Impact factor: 2.823

2.  Conformational Restriction Leading to a Selective CB2 Cannabinoid Receptor Agonist Orally Active Against Colitis.

Authors:  Jamal El Bakali; Giulio G Muccioli; Mathilde Body-Malapel; Madjid Djouina; Frédérique Klupsch; Alina Ghinet; Amélie Barczyk; Nicolas Renault; Philippe Chavatte; Pierre Desreumaux; Didier M Lambert; Régis Millet
Journal:  ACS Med Chem Lett       Date:  2014-12-04       Impact factor: 4.345

3.  Quinoline: A versatile heterocyclic.

Authors:  Akranth Marella; Om Prakash Tanwar; Rikta Saha; Mohammad Rahmat Ali; Sandeep Srivastava; Mymoona Akhter; Mohammad Shaquiquzzaman; Mohammad Mumtaz Alam
Journal:  Saudi Pharm J       Date:  2012-03-29       Impact factor: 4.330

4.  Immune-modulation and properties of absorption and blood brain barrier permeability of 1,8-naphthyridine derivatives.

Authors:  Anna Maria Malfitano; Chiara Laezza; Giuseppe Saccomanni; Tiziano Tuccinardi; Clementina Manera; Adriano Martinelli; Elena Ciaglia; Simona Pisanti; Mario Vitale; Patrizia Gazzerro; Maurizio Bifulco
Journal:  J Neuroimmune Pharmacol       Date:  2013-10-01       Impact factor: 4.147

5.  CoMFA and CoMSIA analyses on 4-oxo-1,4-dihydroquinoline and 4-oxo-1,4-dihydro-1,5-, -1,6- and -1,8-naphthyridine derivatives as selective CB2 receptor agonists.

Authors:  Elena Cichero; Sara Cesarini; Luisa Mosti; Paola Fossa
Journal:  J Mol Model       Date:  2009-10-01       Impact factor: 1.810

6.  Effects on immune cells of a new 1,8-naphthyridin-2-one derivative and its analogues as selective CB2 agonists: implications in multiple sclerosis.

Authors:  Anna Maria Malfitano; Chiara Laezza; Alba D'Alessandro; Claudio Procaccini; Giuseppe Saccomanni; Tiziano Tuccinardi; Clementina Manera; Marco Macchia; Giuseppe Matarese; Patrizia Gazzerro; Maurizio Bifulco
Journal:  PLoS One       Date:  2013-05-01       Impact factor: 3.240

7.  Benzoquinoline amines - Key intermediates for the synthesis of angular and linear dinaphthonaphthyridines.

Authors:  Kolandaivel Prabha; K J Rajendra Prasad
Journal:  J Adv Res       Date:  2014-03-05       Impact factor: 10.479

8.  Anti-Proliferative Properties and Proapoptotic Function of New CB2 Selective Cannabinoid Receptor Agonist in Jurkat Leukemia Cells.

Authors:  Antonella Capozzi; Vincenzo Mattei; Stefano Martellucci; Valeria Manganelli; Giuseppe Saccomanni; Tina Garofalo; Maurizio Sorice; Clementina Manera; Roberta Misasi
Journal:  Int J Mol Sci       Date:  2018-07-04       Impact factor: 5.923
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.